YmAbs Therapeutics (YMAB)
(Real Time Quote from BATS)
$11.64 USD
+0.04 (0.35%)
Updated May 20, 2024 01:52 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Brokerage Reports
Y-mAbs Therapeutics, Inc. [YMAB]
Reports for Purchase
Showing records 141 - 148 ( 148 total )
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Most Recent Priority Review Voucher Sale Price is Incrementally Positive for Y-mAbs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financials Reported; On the Cusp of Dual Regulatory Filings; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Regulatory Submission FDA Meeting Confirms Naxitamab Filing Timeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BLA Filings are On-Track for FDA Submission by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Incorporating Diffuse Intrinsic Pontine Glioma Into Our Forecasts Post-ASCO; Reiterate Buy; Raising PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naxitamab''s ASCO Data May Expand Patient Pool; 1Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Y-mAbs Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Small Is Beautiful; Targeting Orphan Markets With Next- Gen Monoclonal Antibodies; Initiating at Buy and $36 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R